Neuroblastoma Clinical Trials in Boston, Massachusetts

10 studies are recruiting for neuroblastoma in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

   This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuxima…

   Stage

   Phase 3

   Ages

   Up to 30

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   179 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06172296 on ClinicalTrials.gov

2. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

3. B7-H3.CD28Z.CART in Solid Tumors

   The goal of this research study is to test if a new cell therapy (B7-H3.CD28Z.CART / B7-H3 CAR T cells) is safe and effective in treating children and young adults with solid cancers whose tumors have returned or stopped responding to standard treatments (relapsed or refractory) and have been ident…

   Stage

   Phase 1

   Ages

   0 to 30

   Site

   Dana Farber Cancer Institite, Boston, Massachusetts

   Run by

   Robbie Majzner

   See if you can join NCT07358260 on ClinicalTrials.gov

4. Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

   This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lor…

   Stage

   Phase 3

   Ages

   1 to 30

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   164 in total

   Run by

   Children's Oncology Group

   See if you can join NCT03126916 on ClinicalTrials.gov

5. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

6. NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

   This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.

   Stage

   Phase 2

   Ages

   1 to 31

   Site

   Boston Children's Hospital, Dana-Farber Cancer Institute., Boston, Massachusetts

   Locations

   13 in total

   Run by

   New Approaches to Neuroblastoma Therapy Consortium

   See if you can join NCT06450041 on ClinicalTrials.gov

7. Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

   This research is being done to investigate a treatment regimen of Irinotecan, Temozolomide, and Sargramostin, and an immunotherapy called Naxitamab and whether giving Naxitamab more slowly reduces the side effects for participants with relapsed or refractory neuroblastoma. The name of the study dru…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Steven DuBois, MD

   See if you can join NCT07027748 on ClinicalTrials.gov

8. Neuroblastoma Biology Study

   Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and n…

   Stage

   Not phased

   Ages

   0 to 99

   Site

   Children's Hospital Boston, Boston, Massachusetts

   Locations

   17 in total

   Run by

   New Approaches to Neuroblastoma Therapy Consortium

   See if you can join NCT01587300 on ClinicalTrials.gov

9. Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

   The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered…

   Stage

   Not phased

   Ages

   Up to 17

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06831552 on ClinicalTrials.gov

10. MCT for the Harvard/UCSF ROBIN Center

    The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that unde…

    Stage

    Not phased

    Ages

    Any age

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT06000787 on ClinicalTrials.gov